On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
Novo Nordisk Pharma said on March 13 that it has obtained Japanese approval for three types of single-dose subcutaneous devices for its once-weekly GLP-1 agent Ozempic (semaglutide), which has been pending listing since its approval two years ago. Ozempic was…
To read the full story
Related Article
BUSINESS
- Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
- MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
January 28, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
- Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
January 27, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…